The content on this site is intended for healthcare professionals only
Prof Maury presents, at a press conference at ASH 2015, results of the GRAALL-R 2005 study in which the addition of rituximab to standard chemotherapy was found to improve the outcome of adult patients with CD20-positive, Ph-negative, B-cell precursor acute lymphoblastic leukaemia (ALL).
The primary endpoint of event-free survival was increased from 52% with standard chemotherapy to 65% at 6 years when rituximab was added, Dr Maury says. Overall survival was about 60%. The latter appeared higher if patients who had received an allogeneic stem cell transplant at the time of their first complete remission were censored from the analysis.
Read the news story or watch the video interview for more information
Read the news story for more information.
KRdc as induction therapy shows improved OS for NDMM patients
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Guiding transplant decisions in multiple myeloma with MRD
Advancements in paediatric Acute lymphoblastic leukemia management
Status of anti BCMA therapy in myeloma
Multiple myeloma In Rwanda: The need for further research
Addressing the rise of multiple myeloma in Rwanda
GIST tumours and soft tissue sarcomas
